Infections of diabetic foot ulcers with methicillin-resistant staphylococcus aureus

International Journal of Lower Extremity Wounds

Volumn 14, Issue 1, 2015, Pages 44-49

  Cervantes García, Estrella ^a,b   García González, Rafael ^b   Reséndiz Albor, Aldo ^b   Salazar Schettino, Paz Maria ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

diabetic foot; infection; methicillin resistance; microbiota; MRSA; Staphylococcus aureus; type 2 diabetes mellitus

Indexed keywords

CEFOXITIN; ANTIINFECTIVE AGENT;

ABSCESS; ADULT; AGE; AGED; ARTICLE; CELLULITIS; DIABETIC FOOT; ESCHERICHIA COLI; FEMALE; GANGRENE; HUMAN; INFECTED DIABETIC FOOT; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MEXICO; NON INSULIN DEPENDENT DIABETES MELLITUS; PENICILLIN RESISTANCE; PRIORITY JOURNAL; SEX DIFFERENCE; AGE DISTRIBUTION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDY; SEX RATIO; STAPHYLOCOCCAL INFECTIONS; YOUNG ADULT;

ADULT; AGE DISTRIBUTION; AGED; ANTI-BACTERIAL AGENTS; DIABETIC FOOT; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MEXICO; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; SEX DISTRIBUTION; STAPHYLOCOCCAL INFECTIONS; YOUNG ADULT;

EID: 84927510647     PISSN: 15347346     EISSN: 15526941     Source Type: Journal    
DOI: 10.1177/1534734614564053     Document Type: Article

References (25)

1. Wild S, Rogelic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 ; 27: 1047-1053
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2020 and 2030. Diabetes Res Clin Pract. 2010 ; 87: 4-14
3. Boulton AJ, Vileikyte L, Ragmarson-Tennval G, Apelquist J. The global burden of diabetic foot disease. Lancet. 2005 ; 366: 1719-1724
4. Boulton AJ, Kirner RS, Vileikyte L. Clinical practice: neurophatic diabetic foot ulcers. N Engl J Med. 2004 ; 35: 48-55
5. Lavery LA, Armstrong DG, Murdoch DP, Peters EJ, Lipsky BA. Validation of the Infectious Diseases Society of America's diabetic foot infection classification system. Clin Infect Dis. 2007 ; 44: 562-565
6. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004 ; 9: 885-910
7. Dang CN, Prasad YD, Boulton AJ, Jude EB. Methicillin-resistant Staphylococcus aureus in diabetic foot clinic: a worsening problem. Diabet Med. 2003 ; 20: 159-161
8. Citron DM, Goldstein EJ, Merrian CV, Lipsky BA, Abramson MA. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol. 2007 ; 45: 2819-2820
9. Kandamir O, Akbay E, Sakin E, Milcan A, Gen K. Risk factors for infection of the diabetic foot with multiantibiotic resistant microorganisms. J Infect. 2007 ; 54: 439-445
10. Shanakar EM, Mohan V, Premalatha G, Srinivasan RS, Usha AR. Bacterial etiology of diabetic foot infections in South India. Eur J Intern Med. 2005 ; 16: 567-570
11. Eleftheriadou I, Tentolouris N, Argiana V, Jude E, Boulton AJ. Methicillin-resistant Staphylococcus aureus in diabetic foot infections. Drugs. 2010 ; 70: 1785-1797
12. Tentolouris NJ, Smirnof EB, Knowles EA, Boulton AJ. Methicillin resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med. 1999 ; 16: 767-771
13. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003 ; 348: 1342-1347
14. Howden BP, Davis JK, Johnson PDR, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection and clinical implications. Clin Microbiol Rev. 2010 ; 23: 99-139
15. Hartemann-Heutier A, Robert J, Jacqueminet S, et al. Diabetic foot ulcers and multidrug resistant organisms risk factors and impact. Diabet Med. 2004 ; 21: 710-715
16. David L, Peterson R, Bonomo A. Extended spectrum beta lactamase: a clinical update. Clin Microbiol Rev. 2005 ; 18: 657-686
17. Wagner FW. The dysvascular foot: a system for diagnosis and treatment. Foot Ankle. 1981 ; 2: 64-122
18. Majno G, Joris I Cells, Tissues, and Disease: Principles of General Pathology. 2 nd ed.Oxford, UK: Oxford University Press; 2004. Oxford, UK: Oxford University Press ; 2004 :
19. Performance Standards for Antimicrobial Susceptibility Testing; Approved Standard. 10 th ed.Wayne, PA: CLSI; 2011. Wayne, PA: CLSI ; 2011 :
20. Gravetter FJ, Wallnau LB Statistics for the Behavioral Sciences. 7 th ed.Belmont, CA: Thomson Wadsworth; 2007. Belmont, CA: Thomson Wadsworth ; 2007 :
21. Tentolouris N, Petrikkos G, Vallianou N, et al. Prevalence of methicillin resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin Microbiol Infect. 2006 ; 12: 186-189
22. Sotto A, Lina G, Richard JL, et al. Virulence potential of Staphylococcus aureus strains isolated from diabetic foot ulcers: a new paradigm. Diabetes Care. 2008 ; 31: 2318-2324
23. Mendes JJ, Marques-Costa C, Villela J, et al. Clinical and bacteriological survey of diabetic foot infections in Lisbon. Diabetes Res Clin Pract. 2012 ; 95: 153-161
24. Gadapelli R, Dhawn B, Sreenivas V, Kapil A, Ammini AC, Chaudhtry RA. Clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. Diabetes Care. 2006 ; 29: 1727-1732
25. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin resistant Staphylococcus aureus (MRSA) infection resistant previous use of antimicrobials. J Antimicrob Chemother. 2002 ; 49: 999-1005